Search

Your search keyword '"Devoe, Craig"' showing total 75 results

Search Constraints

Start Over You searched for: Author "Devoe, Craig" Remove constraint Author: "Devoe, Craig" Database Unpaywall Remove constraint Database: Unpaywall
75 results on '"Devoe, Craig"'

Search Results

1. Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.

2. AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma.

3. DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.

4. Abstract C092: T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile lymph node targeted mutant KRAS vaccine

5. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

6. Table S3 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

7. Table S1 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

8. Table S3 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

9. Table S2 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

10. Data from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

11. Supplemental Figures from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

12. Table S5 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

13. Data from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

14. Supplemental Table Legends from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

15. Table S2 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

16. Table S5 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

17. Table S4 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

18. Supplemental Figures from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

19. Table S1 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

20. Supplemental Figure Legends from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

21. Supplemental Table Legends from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

22. Supplemental Figure Legends from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

23. Table S4 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

24. Supplementary Tables 1-2 and Supplementary Figures 1-2 from Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

25. Supplementary Tables 1-2 and Supplementary Figures 1-2 from Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

26. Supplemental Tables and Figures from Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

27. Supplemental Tables and Figures from Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

28. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

30. First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.

31. The Amyloidoses

33. CTNI-45. RESPONSE EVALUATION OF AR-67 FROM A PHASE-2 RECURRENT GLIOBLASTOMA TRIAL BY ARTIFICIAL INTELLIGENCE ASSISTED TUMOR VOLUMETRIC ESTIMATION: COMPARISON WITH THE SUM OF THE PERPENDICULAR DIAMETERS PRODUCT

35. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant

39. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

41. ACTR-40. PHASE 2 SAFETY AND EFFICACY OF AR-67 (7-T-BUTYLDIMETHYLSILTYL-10-HYDROXYCAMPTOTHECIN) IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) OR GLIOSARCOMA

47. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

49. Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

50. Genomic Profiling of Small-Bowel Adenocarcinoma

Catalog

Books, media, physical & digital resources